Cargando…
Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat
The application of erythropoietin (EPO) can bring about a rare but serious complication called anti‐EPO antibody‐mediated pure red cell aplasia (PRCA). Once the disease is diagnosed, EPO administration should be stopped immediately. However, after the removal of the anti‐EPO antibody, treating anaem...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754494/ https://www.ncbi.nlm.nih.gov/pubmed/32856389 http://dx.doi.org/10.1111/ijlh.13325 |
_version_ | 1783626208518340608 |
---|---|
author | Wu, Yunzhou Cai, Xudong Ni, Jianing Lin, Xiaomeng |
author_facet | Wu, Yunzhou Cai, Xudong Ni, Jianing Lin, Xiaomeng |
author_sort | Wu, Yunzhou |
collection | PubMed |
description | The application of erythropoietin (EPO) can bring about a rare but serious complication called anti‐EPO antibody‐mediated pure red cell aplasia (PRCA). Once the disease is diagnosed, EPO administration should be stopped immediately. However, after the removal of the anti‐EPO antibody, treating anaemia in these patients with chronic renal disease with EPO therapy is difficult, as restarting EPO therapy risks the recurrence of anti‐EPO antibody‐mediated PRCA. A 26‐year‐old man with anaemia related to renal failure, who was administered recombinant human EPO subcutaneously, developed anti‐EPO antibody‐mediated PRCA. After removal of antibodies by treatment with corticosteroids and cyclosporine, therapy for anaemia of chronic renal disease with roxadustat achieved good results. Roxadustat is a new type of drug for the treatment of anaemia, and it can stimulate endogenous EPO within or near the physiologic range and increase haemoglobin levels. |
format | Online Article Text |
id | pubmed-7754494 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | John Wiley and Sons Inc. |
record_format | MEDLINE/PubMed |
spelling | pubmed-77544942020-12-28 Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat Wu, Yunzhou Cai, Xudong Ni, Jianing Lin, Xiaomeng Int J Lab Hematol Letter to the Editors The application of erythropoietin (EPO) can bring about a rare but serious complication called anti‐EPO antibody‐mediated pure red cell aplasia (PRCA). Once the disease is diagnosed, EPO administration should be stopped immediately. However, after the removal of the anti‐EPO antibody, treating anaemia in these patients with chronic renal disease with EPO therapy is difficult, as restarting EPO therapy risks the recurrence of anti‐EPO antibody‐mediated PRCA. A 26‐year‐old man with anaemia related to renal failure, who was administered recombinant human EPO subcutaneously, developed anti‐EPO antibody‐mediated PRCA. After removal of antibodies by treatment with corticosteroids and cyclosporine, therapy for anaemia of chronic renal disease with roxadustat achieved good results. Roxadustat is a new type of drug for the treatment of anaemia, and it can stimulate endogenous EPO within or near the physiologic range and increase haemoglobin levels. John Wiley and Sons Inc. 2020-08-27 2020-12 /pmc/articles/PMC7754494/ /pubmed/32856389 http://dx.doi.org/10.1111/ijlh.13325 Text en © 2020 The Authors. International Journal of Laboratory Hematology published by John Wiley & Sons Ltd This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Letter to the Editors Wu, Yunzhou Cai, Xudong Ni, Jianing Lin, Xiaomeng Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat |
title | Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat |
title_full | Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat |
title_fullStr | Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat |
title_full_unstemmed | Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat |
title_short | Resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat |
title_sort | resolution of epoetin‐induced pure red cell aplasia, successful re‐challenge with roxadustat |
topic | Letter to the Editors |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7754494/ https://www.ncbi.nlm.nih.gov/pubmed/32856389 http://dx.doi.org/10.1111/ijlh.13325 |
work_keys_str_mv | AT wuyunzhou resolutionofepoetininducedpureredcellaplasiasuccessfulrechallengewithroxadustat AT caixudong resolutionofepoetininducedpureredcellaplasiasuccessfulrechallengewithroxadustat AT nijianing resolutionofepoetininducedpureredcellaplasiasuccessfulrechallengewithroxadustat AT linxiaomeng resolutionofepoetininducedpureredcellaplasiasuccessfulrechallengewithroxadustat |